ORIDOPA (Orion Pharma (AUS) Pty Limited)
Product name
ORIDOPA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
137 (255 working days)
Active ingredients
carbidopa monohydrate, levodopa
Registration type
New generic medicine
Indication
ORIDOPA 100/25 is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. ORIDOPA 100/25 frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.